BTS 74,398

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BTS 74,398
BTS74398 structure.png
PubChem CID
Chemical and physical data
Molar mass418.423 g/mol g·mol−1
3D model (JSmol)

BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2][3] but was unsuccessful in human trials.[4]


  1. ^ Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. Journal of Pharmacology and Experimental Therapeutics. 2005 Mar;312(3):1124-31. PMID 15542624
  2. ^ Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Movement Disorders. 2004 Jan;19(1):15-21. PMID 14743355
  3. ^ Lane EL, Cheetham SC, Jenner P. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. European Journal of Neuroscience. 2005 Jan;21(1):179-86. PMID 15654855
  4. ^ Lane EL, Cheetham S, Jenner P. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission. 2008;115(3):423-9. PMID 18250952